SCHEMBL4583306

SCHEMBL4583306

Cc1ccccc1NC(=S)NC1CCN(c2nncc3cc(Br)ccc23)CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
KMT2A Q03164 4/20 0.43
LMNA P02545 3/20 0.43
MEN1 O00255 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
MAPK14 Q16539 2/20 0.42
LCK P06239 1/20 0.42
KIT P10721 1/20 0.42
KDR P35968 1/20 0.42
MAPK9 P45984 1/20 0.42
GAA P10253 1/20 0.40
ALOX12 P18054 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4582189 0.93 ALDH1A1 (0.48) ALDH1A1KMT2ALMNAMEN1SMN1; SMN2
SCHEMBL4583301 0.91 KMT2A (0.43) ALDH1A1KMT2ALMNAMEN1SMN1; SMN2
SCHEMBL4583961 0.89 HTT (0.49) ALDH1A1KMT2ALMNAMEN1SMN1; SMN2
SCHEMBL4582792 0.89 ALDH1A1 (0.51) ALDH1A1KMT2ALMNAMEN1SMN1; SMN2
SCHEMBL4582502 0.87 KMT2A (0.48) ALDH1A1KMT2ALMNAMEN1SMN1; SMN2
SCHEMBL4582336 0.86 PKM (0.49) ALDH1A1KMT2ALMNAMEN1SMN1; SMN2
SCHEMBL4728090 0.85 KMT2A (0.40) ALDH1A1KMT2AMEN1SMN1; SMN2MAPT
SCHEMBL4583133 0.85 SMN1; SMN2 (0.46) ALDH1A1KMT2ALMNASMN1; SMN2RAB9A
SCHEMBL4583182 0.85 KMT2A (0.39) ALDH1A1KMT2ALMNAMEN1SMN1; SMN2
SCHEMBL4584119 0.84 MAPK14 (0.44) KMT2ALMNASMN1; SMN2MAPK14ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080125435-A1 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2008-05-29 US claimed
EP-1903037-A1 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2008-03-26 EP claimed
WO-2008028690-A1 1-(HET)ARYL-3-[HETARYL-PIPERIDIN-4-YL]-THIOUREAS AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-13 WO claimed
US-20080125435-A1 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2008-05-29 US disclosed
EP-1903037-A1 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2008-03-26 EP disclosed
WO-2008028690-A1 1-(HET)ARYL-3-[HETARYL-PIPERIDIN-4-YL]-THIOUREAS AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125435-A1 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor PTGER2, PTGER1, PTGES2 ALDH1A1 866/4885KMT2A 2513/4885LMNA 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.